AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24839031 — intervention group
Group type: COMPARATOR
Intervention: Physician expectations
Number of subjects: 3280
Study 24840041 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent iodine-125 seed implantation (PI)
Number of subjects: 6927
Study 24840763 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal and lower-extremity compression during head-upright tilt table testing
Number of subjects: 20
Study 24842896 — intervention group
Group type: COMPARATOR
Intervention: PCOS women (cohort-1)
Number of subjects: 100
Study 24842896 — intervention group
Group type: COMPARATOR
Intervention: PCOS women (cohort-2)
Number of subjects: 100
Study 24843058 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 1
Study 24843416 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp70 (thrice-daily injections)
Number of subjects: 289
Study 24843486 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg
Number of subjects: 179
Study 24843486 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg
Number of subjects: 179
Study 24843486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 24843499 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg/day
Number of subjects: 264
Study 24843499 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.9 mg/day
Number of subjects: 264
Study 24843499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 24843499 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 264
Study 24843518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg/day
Number of subjects: 134
Study 24843518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 24843520 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus low-dose pravastatin (10-20 mg/day, average 8.3 mg during follow-up)
Number of subjects: 7832
Study 24843520 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 7832
Study 24843528 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg/day
Number of subjects: 400
Study 24843528 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide 1.25-2.5 mg/day
Number of subjects: 400
Study 24843530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day
Number of subjects: 123
Study 24843529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg
Number of subjects: 117
Study 24843529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg
Number of subjects: 117
Study 24843529 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 117
Study 24843582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg ginsam
Number of subjects: 72
Study 24843582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg ginsam
Number of subjects: 72
Study 24843582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg ginsam
Number of subjects: 72
Study 24843582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24843595 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg (n=268)
Number of subjects: 664
Study 24843595 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.6 mg, 0.9 mg (n=176)
Number of subjects: 664
Study 24843595 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide 2.5 mg (n=132; trial A)
Number of subjects: 664
Study 24843595 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=88; trial B)
Number of subjects: 664
Study 24843617 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg + glimepiride
Number of subjects: 0
Study 24843617 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg + glimepiride
Number of subjects: 0
Study 24843617 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride monotherapy
Number of subjects: 0
Study 24843617 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin + glimepiride (both dosages)
Number of subjects: 0
Study 24843631 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once-weekly (EQW)
Number of subjects: 681
Study 24843631 — intervention group
Group type: COMPARATOR
Intervention: Exenatide twice-daily (EBID)
Number of subjects: 681
Study 24843632 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 65
Study 24843632 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 65
Study 24843649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once daily
Number of subjects: 149
Study 24843649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 24843650 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 136
Study 24843697 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy (10, 20, and 40 mg)
Number of subjects: 440
Study 24843710 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin regimen change
Number of subjects: 625
Study 24843712 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily
Number of subjects: 204
Study 24843712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 24843714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg/day
Number of subjects: 133
Study 24843714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 24843715 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 435
Study 24843715 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 435
Study 24843716 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 1 mg
Number of subjects: 100
Study 24843716 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 100
Study 24843716 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 100
Study 24843716 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 100
Study 24843716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24843767 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric high-protein diet (HP group)
Number of subjects: 18
Study 24843767 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (ST group)
Number of subjects: 18
Study 24843767 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HP and ST groups
Number of subjects: 18
Study 24843782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily
Number of subjects: 81
Study 24843782 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,000 mg daily
Number of subjects: 81
Study 24843782 — intervention group
Group type: COMPARATOR
Intervention: Metformin and Pioglitazone (comparison)
Number of subjects: 81
Study 24844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric symptomatology and problem behaviour assessment using standardised instruments.
Number of subjects: 600
Study 24844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs for care assessment using standardised instruments.
Number of subjects: 600
Study 24844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using standardised instruments.
Number of subjects: 600
Study 24844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver burden assessment using standardised instruments.
Number of subjects: 600
Study 24844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services utilisation assessment using standardised instruments.
Number of subjects: 600
Study 24844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs for care assessment using standardised instruments.
Number of subjects: 600
Study 24844270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of mental healthcare assessment through open questions and problem-focused interviews.
Number of subjects: 600
Study 24844673 — intervention group
Group type: EXPERIMENTAL
Intervention: PDPN-positive/EpCAM-positive CTC ratio >20%
Number of subjects: 53
Study 24844912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 0
Study 24844950 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 52
Study 24846037 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-directed therapy
Number of subjects: 1007
Study 24846037 — intervention group
Group type: COMPARATOR
Intervention: Any oncogenic driver(s) without genotype-directed therapy
Number of subjects: 1007
Study 24846037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogenic drivers detected
Number of subjects: 1007
Study 24846037 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched targeted therapy or trial
Number of subjects: 1007
Study 24846496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg oral dose
Number of subjects: 10
Study 24846496 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 10
Study 24847016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonobstructive CAD
Number of subjects: 117
Study 24847016 — intervention group
Group type: COMPARATOR
Intervention: Obstructive CAD
Number of subjects: 117
Study 24848067 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]5-hydroxy-tryptophan ([(11)C]5-HTP)
Number of subjects: 19
Study 24848086 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) during bladder tasks with warm saline (37°C)
Number of subjects: 0
Study 24848086 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) during bladder tasks with cold saline (4-8°C)
Number of subjects: 0
Study 24848086 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL warm saline starting with an empty bladder
Number of subjects: 0
Study 24848086 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL warm saline starting with a low prefilled bladder volume (100 mL)
Number of subjects: 0
Study 24848086 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL warm saline starting with a high prefilled bladder volume (persistent desire to void)
Number of subjects: 0
Study 24848086 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL cold saline starting with an empty bladder
Number of subjects: 0
Study 24849582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib + Paclitaxel/Carboplatin
Number of subjects: 97
Study 24849582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib + Carboplatin/Etoposide
Number of subjects: 97
Study 24849582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib (100-800 mg/day every 21 days)
Number of subjects: 97
Study 24849582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuvatinib
Number of subjects: 97
Study 24849582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 97
Study 24849710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, outpatient, behavioral weight management program
Number of subjects: 66
Study 24849854 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24850369 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline amotivation
Number of subjects: 754
Study 24850369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognition
Number of subjects: 754
Study 24850369 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational deficits
Number of subjects: 754
Study 24850369 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive deficits
Number of subjects: 754
Study 24850369 — intervention group
Group type: EXPERIMENTAL
Intervention: Heinrichs-Carpenter Quality of Life Scale
Number of subjects: 754
Study 24852804 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Orbital Atherectomy System (OAS)
Number of subjects: 443
Study 24852920 — intervention group
Group type: EXPERIMENTAL
Intervention: SR Fampridine 10 mg BID for 4 weeks
Number of subjects: 108
Study 24853169 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole 5-8 mg/kg/day BID for 60 days
Number of subjects: 40
Study 24853169 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole plasma concentrations in children
Number of subjects: 40
Study 24853169 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole treatment in children under 7 years
Number of subjects: 40
Study 24853169 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of clearance rates
Number of subjects: 40
Study 24854384 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged type 2 diabetes (MA-DM)
Number of subjects: 50
Study 24854384 — intervention group
Group type: COMPARATOR
Intervention: Aged Type 2 diabetes (A-DM)
Number of subjects: 50
Study 24854384 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged normal glucose tolerance (MA-NGT)
Number of subjects: 50
Study 24854384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged normal glucose tolerance (A-NGT)
Number of subjects: 50
Study 24854384 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (DM)
Number of subjects: 50
Study 24854484 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 129
Study 24854484 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 129
Study 24855165 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized insulin injection technique
Number of subjects: 0
Study 24855165 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin injection technique
Number of subjects: 0
Study 24855212 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, cyclophosphamide, and dexamethasone (CCyd)
Number of subjects: 58
Study 24857248 — intervention group
Group type: EXPERIMENTAL
Intervention: Home discharge
Number of subjects: 304
Study 24857248 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient floor admission
Number of subjects: 304
Study 24857248 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 304
Study 24857248 — intervention group
Group type: COMPARATOR
Intervention: ICU admission vs floor admission
Number of subjects: 304
Study 24857248 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet/anticoagulation therapy
Number of subjects: 304
Study 24857248 — intervention group
Group type: EXPERIMENTAL
Intervention: Skull fracture
Number of subjects: 304
Study 24857248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower GCS
Number of subjects: 304
Study 24857248 — intervention group
Group type: COMPARATOR
Intervention: Level of care
Number of subjects: 304
Study 24857280 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline nasal irrigation (twice daily for 8 weeks)
Number of subjects: 40
Study 24857280 — intervention group
Group type: COMPARATOR
Intervention: Intranasal corticosteroid alone
Number of subjects: 40
Study 24857345 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, escalated by 50 mg every 2 weeks to a maximum of 300 mg/day)
Number of subjects: 49
Study 24858016 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDP patients
Number of subjects: 18
Study 24858016 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study 24858447 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with mild to severe depressive symptoms (PHQ-9 scores ≥5, n=116)
Number of subjects: 242
Study 24858447 — intervention group
Group type: COMPARATOR
Intervention: Caregivers with no depressive symptoms (PHQ-9 scores <5, n=126)
Number of subjects: 242
Study 24859362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1776
Study 24859363 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, rituximab, and dexamethasone (CaRD)
Number of subjects: 20
Study 24859366 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-401 at 12.5 μg/kg intravenously over 15 minutes daily for up to 5 doses
Number of subjects: 11
Study 24859907 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobacumab (three doses of 1.2 mg/kg)
Number of subjects: 31
Study 24859907 — intervention group
Group type: COMPARATOR
Intervention: Control (no panobacumab)
Number of subjects: 31
Study 24860459 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted walking sessions for 45 min, 5 times a week for 4 weeks
Number of subjects: 5
Study 24860718 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC + bevacizumab (n=92)
Number of subjects: 127
Study 24860718 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH + bevacizumab (n=34)
Number of subjects: 127
Study 24860718 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC + bevacizumab
Number of subjects: 127
Study 24860718 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH + bevacizumab
Number of subjects: 127
Study 24861484 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum YKL-40 levels at 32 weeks of gestation
Number of subjects: 1214
Study 24861484 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery pulsatility index at 32 weeks
Number of subjects: 1214
Study 24861484 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum YKL-40 levels
Number of subjects: 1214
Study 24861484 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery notching
Number of subjects: 1214
Study 24861649 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS505 (new iteration of the ESSURE insert)
Number of subjects: 35
Study 24861649 — intervention group
Group type: COMPARATOR
Intervention: ESS305 (previous version of the device)
Number of subjects: 35
Study 24861649 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS505
Number of subjects: 35
Study 24861649 — intervention group
Group type: COMPARATOR
Intervention: ESS305
Number of subjects: 35
Study 24861649 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS505 and ESS305
Number of subjects: 35
Study 24862257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 1884
Study 24862645 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent lacunar infarcts
Number of subjects: 3005
Study 24862645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe white matter hyperintensities
Number of subjects: 3005
Study 24862645 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 3005
Study 24862830 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin; specific dosage and duration not mentioned
Number of subjects: 0
Study 24864123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 36
Study 24865607 — intervention group
Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome patients with skewed X-inactivation
Number of subjects: 73
Study 24865607 — intervention group
Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome patients
Number of subjects: 73
Study 24867540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant short-course proton-based radiation with capecitabine (5 daily doses of 5 GyE)
Number of subjects: 50
Study 24867540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant short-course proton-based radiation with capecitabine
Number of subjects: 50
Study 24867540 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker studies
Number of subjects: 50
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Natrelle round silicone implants (augmentation)
Number of subjects: 715
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Natrelle round silicone implants (revision-augmentation)
Number of subjects: 715
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Natrelle round silicone implants (reconstruction)
Number of subjects: 715
Study 24867717 — intervention group
Group type: COMPARATOR
Intervention: Submuscular placement of implants (augmentation)
Number of subjects: 715
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implants (magnetic resonance imaging cohort)
Number of subjects: 715
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation subjects
Number of subjects: 715
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision-augmentation subjects
Number of subjects: 715
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction subjects
Number of subjects: 715
Study 24867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall breast satisfaction
Number of subjects: 715
Study 24868099 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg per day until disease progression or intolerable adverse events
Number of subjects: 42
Study 24869942 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) after ex vivo elimination of αβ(+) T cells and CD19(+) B cells
Number of subjects: 23
Study 24870935 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (doubling)
Number of subjects: 288
Study 24870935 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer (doubling)
Number of subjects: 288
Study 24870935 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP (1-unit increase)
Number of subjects: 288
Study 24870935 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 and D-dimer score (1-unit increase)
Number of subjects: 288
Study 24871871 — intervention group
Group type: EXPERIMENTAL
Intervention: AnaConDa (ACD) with 0.8% sevoflurane
Number of subjects: 12
Study 24871871 — intervention group
Group type: EXPERIMENTAL
Intervention: AnaConDa (ACD) without sevoflurane
Number of subjects: 12
Study 24871871 — intervention group
Group type: COMPARATOR
Intervention: Conventional heat and moisture exchanger (HME)
Number of subjects: 12
Study 24872229 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin 2 (1.5 million IU/d for 5 days, followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9)
Number of subjects: 5
Study 24872229 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin 2
Number of subjects: 5
Study 24872402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv 375 mg
Number of subjects: 61
Study 24872402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv 750 mg
Number of subjects: 61
Study 24872402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv 500 mg (after dose adjustment)
Number of subjects: 61
Study 24872402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61